LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Xofigo ® (Radium-223-dichlorid) / 2

    Böhmer, Sibylle / Miller, Kurt

    knochengezielte Therapie beim metastasierten kastrationsresistenten Prostatakarzinom

    (Thieme case report ; 7,4)

    2015  

    Author's details [Hrsg. Kurt Miller ... Autoren Sibylle Böhmer ...]
    Series title Thieme case report ; 7,4
    Xofigo ® (Radium-223-dichlorid)
    Collection Xofigo ® (Radium-223-dichlorid)
    Language German
    Size 11 S. : Ill., graph. Darst.
    Publisher Thieme
    Publishing place Stuttgart u.a.
    Publishing country Germany
    Document type Article
    HBZ-ID HT018671002
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6843 -7,4- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Collection: Xofigo ® (Radium-223-dichlorid)

    Böhmer, Sibylle / Miller, Kurt

    knochengezielte Therapie beim metastasierten kastrationsresistenten Prostatakarzinom

    (Thieme case report ; ...)

    2015  

    Author's details [Hrsg. Kurt Miller ... Autoren Sibylle Böhmer ...]
    Series title Thieme case report
    ...
    Language German
    Dates of publication 2015-9999
    Publisher Thieme
    Publishing place Stuttgart u.a.
    Publishing country Germany
    Document type Book ; Collection (display volumes)
    HBZ-ID HT018590797
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article: Xofigo ® (Radium-223-dichlorid) / 1

    Böhmer, Sibylle / Miller, Kurt

    knochengezielte Therapie beim metastasierten kastrationsresistenten Prostatakarzinom

    (Thieme Case Report ; 7,3)

    2015  

    Author's details [Hrsg. Kurt Miller ... Autoren Sibylle Böhmer ...]
    Series title Thieme Case Report ; 7,3
    Thieme case report
    Xofigo ® (Radium-223-dichlorid)
    Collection Thieme case report
    Xofigo ® (Radium-223-dichlorid)
    Language German
    Size 15 S. : Ill., graph. Darst.
    Publisher Thieme
    Publishing place Stuttgart u.a.
    Publishing country Germany
    Document type Article
    HBZ-ID HT018590805
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6843 -7,3- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Xofigo ® (Radium-223-dichlorid) / 3

    Böhmer, Sibylle / Miller, Kurt

    knochengezielte Therapie beim metastasierten kastrationsresistenten Prostatakarzinom

    (Thieme case report ; 7,6)

    2015  

    Author's details [Hrsg. Kurt Miller ... Autoren Sibylle Böhmer ...]
    Series title Thieme case report ; 7,6
    Xofigo ® (Radium-223-dichlorid)
    Collection Xofigo ® (Radium-223-dichlorid)
    Language German
    Size 15 S. : Ill., graph. Darst.
    Publisher Thieme
    Publishing place Stuttgart u.a.
    Publishing country Germany
    Document type Article
    HBZ-ID HT018723372
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6843 -7,6- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Fall 1. Radium-223-dichlorid: Schmerzfreiheit bei Erhalt der Lebensqualität

    Böhmer, Sibylle

    Thieme case report

    2015  Volume 7, Issue 3, Page(s) 6

    Language German
    Document type Article
    ISSN 1611-7875
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6843: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

    Parker, Christopher C / Coleman, Robert E / Sartor, Oliver / Vogelzang, Nicholas J / Bottomley, David / Heinrich, Daniel / Helle, Svein I / O'Sullivan, Joe M / Fosså, Sophie D / Chodacki, Aleš / Wiechno, Paweł / Logue, John / Seke, Mihalj / Widmark, Anders / Johannessen, Dag Clement / Hoskin, Peter / James, Nicholas D / Solberg, Arne / Syndikus, Isabel /
    Kliment, Jan / Wedel, Steffen / Boehmer, Sibylle / Dall'Oglio, Marcos / Franzén, Lars / Bruland, Øyvind S / Petrenciuc, Oana / Staudacher, Karin / Li, Rui / Nilsson, Sten

    European urology

    2017  Volume 73, Issue 3, Page(s) 427–435

    Abstract: Background: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 ...

    Abstract Background: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.
    Objective: To report updated ALSYMPCA safety, including long-term safety up to 3 yr after the first injection.
    Design, setting, and participants: Safety analyses from phase 3 randomized ALSYMPCA trial included patients receiving ≥1 study-drug injection (600 radium-223 and 301 placebo). Patients (405 radium-223 and 167 placebo) entered long-term safety follow-up starting 12 wk after the last study-drug injection, to 3 yr from the first injection. Forty-eight of 405 (12%) radium-223 and 12/167 (7%) placebo patients completed follow-up, with evaluations every 2 mo for 6 mo, then every 4 mo until 3 yr.
    Outcome measurements and statistical analysis: All adverse events (AEs) were collected until 12 wk after the last injection; subsequently, only treatment-related AEs were collected. Additional long-term safety was assessed by development of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, and secondary malignancies. Data analysis used descriptive statistics.
    Results and limitations: During treatment to 12 wk following the last injection, 564/600 (94%) radium-223 and 292/301 (97%) placebo patients had treatment-emergent AEs (TEAEs). Myelosuppression incidence was low. Grade 3/4 hematologic TEAEs in radium-223 and placebo groups were anemia (13% vs 13%), neutropenia (2% vs 1%), and thrombocytopenia (7% vs 2%). Ninety-eight of 600 (16%) radium-223 and 68/301 (23%) placebo patients experienced grade 5 TEAEs. Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in four radium-223 and three placebo patients. One radium-223 patient had aplastic anemia 16 mo after the last injection. No other cases were observed. Limitations include short (3-yr) follow-up.
    Conclusions: Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns.
    Patient summary: Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection.
    Language English
    Publishing date 2017-07-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2017.06.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top